Confidently Diagnose and Monitor Plasma Cell Disorders with Sebia sFLC Assay

High performance. Clinically validated. Designed for flexibility.
Sebia’s sFLC (serum Free Light Chain) assay offers robust diagnostic support for conditions like multiple myeloma and AL amyloidosis—delivering excellent precision, reproducibility, and flexible ELISA compatibility across platforms. Whether you’re expanding lab capabilities or standardizing workflows, Sebia’s sFLC kits provide the reliability clinicians demand.

Validated precision. Flexible platform integration. Powerful clinical utility.
Sebia’s sFLC assay supports the entire care continuum—from screening and diagnosis to long-term disease monitoring. Compatible with various ELISA platforms and backed by strong sensitivity data, this test supports high-confidence decisions in hematologic disease management.

Download the spec sheet or contact your Sebia representative to validate your ELISA compatibility today.

White Paper from   Brought to you by: